MARKET

RNAZ

RNAZ

Transcode Therapeutics Inc
NASDAQ
1.690
+0.040
+2.42%
After Hours: 1.690 0 0.00% 19:30 09/25 EDT
OPEN
1.600
PREV CLOSE
1.650
HIGH
1.700
LOW
1.600
VOLUME
14.76K
TURNOVER
--
52 WEEK HIGH
20.99
52 WEEK LOW
1.579
MARKET CAP
28.61M
P/E (TTM)
-0.0333
1D
5D
1M
3M
1Y
5Y
1D
TransCode Therapeutics Announces Australia Acceptance Of Patent application, Japan's Issuance Of Notice Of Allowance For Its RNA-Based Therapeutic Platform Technologies
Benzinga · 4d ago
Weekly Report: what happened at RNAZ last week (0914-0918)?
Weekly Report · 5d ago
Weekly Report: what happened at RNAZ last week (0907-0911)?
Weekly Report · 09/14 09:21
TransCode Therapeutics Announces CFO Resignation and Interim Appointment
TipRanks · 09/11 21:26
TransCode Therapeutics Taps Tattory to Be Interim CFO
Dow Jones · 09/10 21:36
TransCode Therapeutics CFO retires
Seeking Alpha · 09/10 20:23
TransCode Therapeutics, CFO Tom Fitzgerald Plans To Retire; John Tattory To Serve As Interim Finance Chief, Effective Immediately
Benzinga · 09/10 20:22
Transcode Therapeutics CFO Fitzgerald retiring, Tattory named interim CFO
TipRanks · 09/10 20:20
More
About RNAZ
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.

Webull offers Transcode Therapeutics Inc stock information, including NASDAQ: RNAZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAZ stock methods without spending real money on the virtual paper trading platform.